Literature DB >> 33593354

The biological function of m6A reader YTHDF2 and its role in human disease.

Jin-Yan Wang1, Ai-Qing Lu2.   

Abstract

N6-methyladenosine (m6A) modification is a dynamic and reversible post-transcriptional modification and the most prevalent internal RNA modification in eukaryotic cells. YT521-B homology domain family 2 (YTHDF2) is a member of m6A "readers" and its role in human diseases remains unclear. Accumulating evidence suggests that YTHDF2 is greatly implicated in many aspects of human cancers and non-cancers through various mechanisms. YTHDF2 takes a great part in multiple biological processes, such as migration, invasion, metastasis, proliferation, apoptosis, cell cycle, cell viability, cell adhesion, differentiation and inflammation, in both human cancers and non-cancers. Additionally, YTHDF2 influences various aspects of RNA metabolism, including mRNA decay and pre-ribosomal RNA (pre-rRNA) processing. Moreover, emerging researches indicate that YTHDF2 predicts the prognosis of different cancers. Herein, we focus on concluding YTHDF2-associated mechanisms and potential biological functions in kinds of cancers and non-cancers, and its prospects as a prognostic biomarker.

Entities:  

Keywords:  Biological function; Cancers; Non-cancers; Up and downregulation; YTHDF2; m6A; signaling pathways

Year:  2021        PMID: 33593354     DOI: 10.1186/s12935-021-01807-0

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  37 in total

Review 1.  Emerging role of dynamic RNA modifications during animal development.

Authors:  Estefanía Sánchez-Vásquez; Nagif Alata Jimenez; Nicolás A Vázquez; Pablo H Strobl-Mazzulla
Journal:  Mech Dev       Date:  2018-04-11       Impact factor: 1.882

2.  Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells.

Authors:  R Desrosiers; K Friderici; F Rottman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

3.  Multivalent m6A motifs promote phase separation of YTHDF proteins.

Authors:  Yifei Gao; Gaofeng Pei; Dongxue Li; Ru Li; Yanqiu Shao; Qiangfeng Cliff Zhang; Pilong Li
Journal:  Cell Res       Date:  2019-08-06       Impact factor: 25.617

4.  N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.

Authors:  Hong Wang; Bei Xu; Jun Shi
Journal:  Gene       Date:  2019-08-24       Impact factor: 3.688

Review 5.  The role of m6A RNA methylation in cancer.

Authors:  Ting Sun; Ruiyan Wu; Liang Ming
Journal:  Biomed Pharmacother       Date:  2019-02-19       Impact factor: 6.529

6.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.

Authors:  Yue Huang; Rui Su; Yue Sheng; Lei Dong; Ze Dong; Hongjiao Xu; Tengfeng Ni; Zijie Scott Zhang; Tao Zhang; Chenying Li; Li Han; Zhenyun Zhu; Fulin Lian; Jiangbo Wei; Qiangqiang Deng; Yungui Wang; Mark Wunderlich; Zhiwei Gao; Guoyu Pan; Dafang Zhong; Hu Zhou; Naixia Zhang; Jianhua Gan; Hualiang Jiang; James C Mulloy; Zhijian Qian; Jianjun Chen; Cai-Guang Yang
Journal:  Cancer Cell       Date:  2019-04-15       Impact factor: 38.585

Review 7.  RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation.

Authors:  Yanan Yue; Jianzhao Liu; Chuan He
Journal:  Genes Dev       Date:  2015-07-01       Impact factor: 11.361

8.  A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation.

Authors:  Shengdong Ke; Endalkachew A Alemu; Claudia Mertens; Emily Conn Gantman; John J Fak; Aldo Mele; Bhagwattie Haripal; Ilana Zucker-Scharff; Michael J Moore; Christopher Y Park; Cathrine Broberg Vågbø; Anna Kusśnierczyk; Arne Klungland; James E Darnell; Robert B Darnell
Journal:  Genes Dev       Date:  2015-09-24       Impact factor: 11.361

9.  ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2.

Authors:  Hongtao Zhu; Xiaoling Gan; Xingwei Jiang; Shuai Diao; Huan Wu; Jianguo Hu
Journal:  J Exp Clin Cancer Res       Date:  2019-04-15

10.  METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.

Authors:  Jie Han; Jing-Zi Wang; Xiao Yang; Hao Yu; Rui Zhou; Hong-Cheng Lu; Wen-Bo Yuan; Jian-Chen Lu; Zi-Jian Zhou; Qiang Lu; Ji-Fu Wei; Haiwei Yang
Journal:  Mol Cancer       Date:  2019-06-22       Impact factor: 27.401

View more
  13 in total

1.  RNA methylation regulators contribute to poor prognosis of hepatocellular carcinoma associated with the suppression of bile acid metabolism: a multi-omics analysis.

Authors:  Tao Zhang; Jian Gu; Xinyi Wang; Jiajia Luo; Jing Yan; Kailin Cai; Huili Li; Yingli Nie; Xiangdong Chen; Jiliang Wang
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  METTL3-Mediated ADAMTS9 Suppression Facilitates Angiogenesis and Carcinogenesis in Gastric Cancer.

Authors:  Nuofan Wang; Xinying Huo; Baoguo Zhang; Xiaoxiang Chen; Shuli Zhao; Xuesong Shi; Hao Xu; Xiaowei Wei
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

3.  YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.

Authors:  Chen-Song Huang; Ying-Qin Zhu; Qiong-Cong Xu; Siyun Chen; Yue Huang; Guangyin Zhao; Xuhao Ni; Bo Liu; Wei Zhao; Xiao-Yu Yin
Journal:  Clin Transl Med       Date:  2022-06

Review 4.  Across Dimensions: Developing 2D and 3D Human iPSC-Based Models of Fragile X Syndrome.

Authors:  Azalea Lee; Jie Xu; Zhexing Wen; Peng Jin
Journal:  Cells       Date:  2022-05-24       Impact factor: 7.666

5.  Mettl14 Attenuates Cardiac Ischemia/Reperfusion Injury by Regulating Wnt1/β-Catenin Signaling Pathway.

Authors:  Ping Pang; Zhezhe Qu; Shuting Yu; Xiaochen Pang; Xin Li; Yuelin Gao; Kuiwu Liu; Qian Liu; Xiuzhu Wang; Yu Bian; Yingqi Liu; Yingqiong Jia; Zhiyong Sun; Hanif Khan; Zhongting Mei; Xiaoqian Bi; Changhao Wang; Xinda Yin; Zhimin Du; Weijie Du
Journal:  Front Cell Dev Biol       Date:  2021-12-16

6.  RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways.

Authors:  Jianwei Qu; Yifan Hou; Qingxiao Chen; Jing Chen; Yi Li; Enfan Zhang; Huiyao Gu; Ruyi Xu; Yang Liu; Wen Cao; Jinna Zhang; Liqin Cao; Jingsong He; Zhen Cai
Journal:  Oncogene       Date:  2021-11-10       Impact factor: 9.867

Review 7.  m6A binding protein YTHDF2 in cancer.

Authors:  Xiaomin Chen; Xiangxiang Zhou; Xin Wang
Journal:  Exp Hematol Oncol       Date:  2022-04-05

8.  The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2.

Authors:  Yiqing Yang; Muisha B Mbikyo; Junzhe Zhang; Yuan Zhang; Naijin Zhang; Zhao Li
Journal:  Cell Death Discov       Date:  2022-04-05

9.  Modification of STIM2 by m6A RNA methylation inhibits metastasis of cholangiocarcinoma.

Authors:  Feng-Qiu Chen; Hao Zheng; Ting Gu; Yu-Hua Hu; Le Yang; Zhi-Ping Huang; Guang-Lei Qiao; Hong-Jie Li
Journal:  Ann Transl Med       Date:  2022-01

10.  Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of Krüppel-like factor 3 (KLF3) promotes osteosarcoma progression.

Authors:  Hong-Jian Shan; Wen-Xiang Gu; Gang Duan; Hong-Liang Chen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.